Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalyst Biosciences, a discoverer and developer of engineered proteases, has got a $4m milestone payment from Pfizer under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.
Subscribe to our email newsletter
Catalyst and Wyeth LLC (the successor to Wyeth), a wholly owned subsidiary of Pfizer, formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second generation Factor VIIa products in June 2009.
Total payments under the collaboration, including an upfront payment of $21m, ongoing research funding, and milestone payments, could exceed $500m, exclusive of double-digit royalty payments.
Catalyst CEO Nassim Usman said that they are very encouraged by the progress made to date in their Factor VIIa program, the most advanced program within Catalyst’s hemostasis franchise.
"In addition to our work with Pfizer, Catalyst has independently achieved significant progress in engineering highly differentiated recombinant human Factor IX and Xa variants for acute and prophylactic treatment of bleeding disorders, including both hemophilia and non-hemophilia indications, Usman said.